| (10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman mesylate |
| (10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman methanesulfonate |
| (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-BENZYL-2-HYDROXY-4-METHYL-5,8-DIOXO-3-OXA-6,9-DIAZATRICYCLO[7.3.0.0(2),?]DODECAN-4-YL]-6-METHYL-6,11-DIAZATETRACYCLO[7.6.1.0(2),?.0(1)(2),(1)?]HEXADECA-1(16),9,12,14-TETRAENE-4-CARBOXAMIDE; METHA |
| (4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),9,12(16),13-tetraene-4-carboxamide; metha |
| (4R,7R)-N-[(1S,2S,4R,7S)-7-BENZYL-2-HYDROXY-4-METHYL-5,8-DIOXO-3-OXA-6,9-DIAZATRICYCLO[7.3.0.0(2),?]DODECAN-4-YL]-6-METHYL-6,11-DIAZATETRACYCLO[7.6.1.0(2),?.0(1)(2),(1)?]HEXADECA-1(16),9,12,14-TETRAENE-4-CARBOXAMIDE; METHANES |
| (6aR,9R,10aR)-N-[(2R,5S,10aS,10bS)-5-Benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxa |
| (6aR,9R)-N-((2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate |
| 11032-41-0 |
| 511-12-6 (Parent) |
| 6190-39-2 |
| 81AXN7R2QT |
| 9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotaman-3',6',18-trione mesylate |
| 9,10-Dihydroergotamine mesylate |
| 9,10-dihydroergotamine methanesulfonate |
| 910882-41-6 |
| AC1L2FO7 |
| AC1LAOVT |
| AC1Q6WD6 |
| ADYPXRFPBQGGAH-UMYZUSPBSA-N |
| AKOS024282478 |
| AN-21195 |
| ANW-42737 |
| C33H37N5O5.CH4O3S |
| CCG-39548 |
| CHEBI:59756 |
| CHEMBL1200517 |
| CHEMBL1396675 |
| CS-2903 |
| CTK8B3562 |
| D 2763 |
| D.H.E. 45 |
| D02211 |
| D0SP3D |
| D2633 |
| DETMS |
| DHE-45 |
| Dihydergot |
| Dihydroergotamine (mesylate) |
| Dihydroergotamine for peak identification, European Pharmacopoeia (EP) Reference Standard |
| Dihydroergotamine mesilate |
| Dihydroergotamine mesilate (JP17) |
| Dihydroergotamine mesilate, European Pharmacopoeia (EP) Reference Standard |
| Dihydroergotamine mesylate (USP) |
| Dihydroergotamine mesylate [USAN:USP] |
| Dihydroergotamine mesylate [USAN] |
| Dihydroergotamine mesylate, United States Pharmacopeia (USP) Reference Standard |
| Dihydroergotamine methanesulfonate |
| Dihydroergotamine methanesulfonate salt |
| Dihydroergotamine methanesulfonate salt, powder |
| Dihydroergotamine monomethanesulfonate |
| DIHYDROERGOTAMINE; METHANESULFONIC ACID |
| Dihydroergotoxin |
| DIHYDROERGOTOXINE |
| Dihytamine |
| DR003475 |
| DR003476 |
| EINECS 228-235-6 |
| Ergoloid dihydroergotoxine |
| Ergoloid Mesylates (dihydroergotoxine) |
| Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy- 2'-methyl-5'-(phenylmethyl)-, (5'?,10?)-, monomethanesulfonate (salt) |
| Ergotamine, 9,10-dihydro-, monomethanesulfonate (salt) |
| Ergotamine, dihydro, methanesulfonate (salt) |
| Ergotoman-3',6',18-trione,9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, monomethanesulfonate (salt) |
| EU-0100357 |
| HMS1920G16 |
| HMS2094K05 |
| HMS2231H03 |
| HMS3261G15 |
| HMS3266C22 |
| HMS3369K10 |
| HMS501N14 |
| HY-B0670A |
| I14-101170 |
| LP00357 |
| LS-64558 |
| MFCD00058615 |
| mide methanesulfonate |
| MLS002153175 |
| MLS002207048 |
| MolPort-003-666-163 |
| MT 300 |
| N-{7-BENZYL-2-HYDROXY-4-METHYL-5,8-DIOXO-3-OXA-6,9-DIAZATRICYCLO[7.3.0.0(2),?]DODECAN-4-YL}-6-METHYL-6,11-DIAZATETRACYCLO[7.6.1.0(2),?.0(1)(2),(1)?]HEXADECA-1(16),9,12,14-TETRAENE-4-CARBOXAMIDE; METHANESULFONIC ACID |
| NCGC00261042-01 |
| Neomigran |
| NSC-759848 |
| NSC759848 |
| Pharmakon1600-01500248 |
| PL001844 |
| PL041420 |
| PL057923 |
| Prestwick_746 |
| rboxamide methanesulfonate(salt) |
| SCHEMBL40843 |
| SCHEMBL40844 |
| SMR001230668 |
| SPECTRUM1500248 |
| SR-01000075382 |
| SR-01000075382-1 |
| ST056346 |
| Tox21_500357 |
| TR-021291 |
| TRA0034972 |
| UNII-81AXN7R2QT |
| Z1544404034 |
